Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04248192 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

Name: Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST) — clinical trial record (NCT04248192)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorCatherine Bollard

Started2020-05-01

View on ClinicalTrials.gov ↗

This is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT).

Amendment history 2 changes detected by DataLookout

2026-08-15

Primary completion pushed: 2025-09 → 2026-11

2026-08-15

Completion pushed: 2026-04 → 2026-12

Trial Details

NCT Number	NCT04248192
Lead Sponsor	Catherine Bollard
Conditions	HIV-Infected Individuals
Enrollment	8 participants
Start Date	2020-05-01
Primary Completion	2026-11 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-14